公开(公告)号：US20240239753A1

公开(公告)日：2024-07-18

申请号：US18562666

申请日：2022-05-20

申请人： CJ CheilJedang Corporation

发明人： Hwayeon LIM ,  Jong Hwan SHIN ,  Hyeongpyo HONG ,  Youn Jae LEE ,  In Sung LEE

IPC分类号： C07D233/64 ,  C07B63/04 ,  C07C229/34 ,  C07D209/20

CPC分类号： C07D233/64 ,  C07B63/04 ,  C07C229/34 ,  C07D209/20

摘要： The present application provides: a method for crystallization of an aromatic amino acid, enabling sustainable cycle of ammonia; and aromatic amino acid crystals produced by the method.

公开(公告)号：US20230348631A1

公开(公告)日：2023-11-02

申请号：US18216888

申请日：2023-06-30

申请人： QUADRIGA BIOSCIENCES, INC.

发明人： BERND JANDELEIT ,  PETER TAM ,  RUIFANG LIU ,  SHIXIANG YAN

IPC分类号： C08B37/16 ,  C07C229/34 ,  A61K9/19 ,  A61K47/69

CPC分类号： C08B37/0015 ,  C07C229/34 ,  A61K9/19 ,  A61K47/6951

摘要： Pharmaceutical compositions comprising a chemotherapeutic agent based on a β-substituted β-amino acid derivative are disclosed. The pharmaceutical compositions include a β-substituted β-amino acid derivative and a cyclodextrin derivative. The pharmaceutical compositions are useful for treating cancer.

公开(公告)号：US11786498B2

公开(公告)日：2023-10-17

申请号：US15737985

申请日：2015-07-02

申请人： Novartis AG

发明人： David Hook ,  Bin Hu ,  Florian Karl Kleinbeck ,  Ulrich Meier ,  Sibylle Mueller ,  Jean-Paul Mutz ,  Jan Schlomach ,  Paul Allen Sutton ,  Liladhar Murlidhar Waykole ,  Bernhard Wietfeld

IPC分类号： A61K31/22 ,  A61P9/10 ,  A61P9/06 ,  A61P25/02 ,  C07C229/34 ,  A61P9/12 ,  A61P25/06 ,  A61K31/4178 ,  A61K31/423

CPC分类号： A61K31/22 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P25/02 ,  A61P25/06 ,  C07C229/34 ,  A61K31/4178 ,  A61K31/423 ,  A61K2300/00 ,  C07B2200/13

摘要： The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.

公开(公告)号：US20230174506A1

公开(公告)日：2023-06-08

申请号：US18060922

申请日：2022-12-01

申请人： Purdue Research Foundation

发明人： Mingii DAI

IPC分类号： C07D401/06 ,  C07D403/06 ,  C07D295/145 ,  C07D491/107 ,  C07D401/14 ,  C07D413/14 ,  C07D409/12 ,  C07D405/14 ,  C07D409/14 ,  C07D209/50 ,  C07C229/34 ,  C07D211/62 ,  C07D211/14 ,  C07D263/56 ,  C07J43/00 ,  C07D311/16 ,  C07D333/34

CPC分类号： C07D401/06 ,  C07D403/06 ,  C07D295/145 ,  C07D491/107 ,  C07D401/14 ,  C07D413/14 ,  C07D409/12 ,  C07D405/14 ,  C07D409/14 ,  C07D209/50 ,  C07C229/34 ,  C07D211/62 ,  C07D211/14 ,  C07D263/56 ,  C07J43/003 ,  C07D311/16 ,  C07D333/34 ,  C07B2200/05

摘要： One-pot synthesis methods for producing amines from activated allenes and derivatives thereof are provided, as well as the compounds produced thereby.

公开(公告)号：US11174220B2

公开(公告)日：2021-11-16

申请号：US17119527

申请日：2020-12-11

申请人： Inspirna, Inc.

发明人： Stephen Wald ,  Eduardo J. Martinez ,  Samuel Stratford ,  Amanda Buist ,  Joseph Benson ,  Jonathan Loughrey

IPC分类号： C07C229/34 ,  A61P35/04

摘要： The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.

公开(公告)号：US20210230192A1

公开(公告)日：2021-07-29

申请号：US17171224

申请日：2021-02-09

申请人： NEUBORON MEDTECH LTD.

发明人： Shi-hong LI ,  Jing HE ,  Heng YAN ,  Fei CAI

IPC分类号： C07F5/02 ,  C07C249/02 ,  C07C229/34 ,  C07B59/00

摘要： A method for preparing 18F-BPA and an intermediate, by which high-purity 18F-BPA is obtained. The method simplifies the synthesis steps after 18F labeling, and is easy to operate and efficient.

公开(公告)号：US20200039917A1

公开(公告)日：2020-02-06

申请号：US16601908

申请日：2019-10-15

申请人： XW Laboratories Inc.

发明人： Jia-Ning Xiang ,  Xuesong Xu ,  Xuan Zhang

IPC分类号： C07C69/78 ,  C07B59/00 ,  C07C69/76 ,  C07C69/24 ,  C07C229/36 ,  C07C69/608 ,  C07C317/44 ,  C07D277/56 ,  C07D211/46 ,  C07C69/738 ,  C07C69/28 ,  C07C255/57 ,  C07D213/79 ,  C07D213/80 ,  C07D309/12 ,  C07C271/22 ,  C07C271/34 ,  C07C69/612 ,  C07D317/64 ,  C07D333/38 ,  C07C229/08 ,  C07C233/47 ,  C07D207/16 ,  C07D307/68 ,  C07C69/22 ,  C07C69/34 ,  C07C69/618 ,  C07C69/74 ,  C07C69/96 ,  C07C229/34 ,  C07C317/14 ,  C07D207/12 ,  C07D211/44 ,  C07D277/30

摘要： The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

公开(公告)号：US20190380993A1

公开(公告)日：2019-12-19

申请号：US16555766

申请日：2019-08-29

申请人： Milestone Pharmaceuticals Inc.

发明人： Martin P. MAGUIRE ,  Elise RIOUX ,  Harry J. LEIGHTON

IPC分类号： A61K31/277 ,  A61K31/275 ,  C07C255/42 ,  C07C255/43 ,  C07C229/34 ,  C07C229/38 ,  A61K31/216 ,  A61K31/26

摘要： The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

公开(公告)号：US10457627B2

公开(公告)日：2019-10-29

申请号：US15762559

申请日：2016-09-22

申请人： XW LABORATORIES INC.

发明人： Jia-Ning Xiang ,  Xuesong Xu ,  Xuan Zhang

IPC分类号： A61K31/221 ,  C07C69/34 ,  C07C69/78 ,  C07C69/24 ,  C07C69/76 ,  C07B59/00 ,  C07C255/57 ,  C07D213/79 ,  C07D213/80 ,  C07D309/12 ,  C07C271/22 ,  C07C271/34 ,  C07C69/28 ,  C07C69/608 ,  C07C69/612 ,  C07C69/738 ,  C07D317/64 ,  C07D333/38 ,  C07C317/44 ,  C07C229/08 ,  C07C229/36 ,  C07C233/47 ,  C07D207/16 ,  C07D277/56 ,  C07D211/46 ,  C07D307/68 ,  C07C69/22 ,  C07C69/618 ,  C07C69/74 ,  C07C69/96 ,  C07C229/34 ,  C07C317/14 ,  C07D207/12 ,  C07D211/44 ,  C07D277/30

摘要： The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

公开(公告)号：US20190210992A1

公开(公告)日：2019-07-11

申请号：US16354011

申请日：2019-03-14

申请人： TEXAS HEART INSTITUTE

发明人： Ronald J. BIEDIGER ,  Robert V. MARKET ,  Michael M. SAVAGE

IPC分类号： C07D333/20 ,  C07D409/14 ,  C07D275/02 ,  C07D409/12 ,  C07D333/10 ,  A61K35/51 ,  A61K35/17 ,  C07D333/24 ,  A61K35/12 ,  C07C229/34 ,  C07C271/22 ,  C07D317/60 ,  C07D213/64 ,  C07C311/08 ,  C07C271/20 ,  C07D413/14

CPC分类号： C07D333/20 ,  A61K35/12 ,  A61K35/17 ,  A61K35/51 ,  C07C229/34 ,  C07C271/20 ,  C07C271/22 ,  C07C311/08 ,  C07D213/64 ,  C07D275/02 ,  C07D317/60 ,  C07D333/10 ,  C07D333/24 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14

摘要： A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4fβ1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.